BioCryst Pharmaceuticals, Inc.
No trades
Fundamentals and stats
EPS and revenue snapshot
In the last quarter, the company reported 1.12 USD per share, beating the 0.05 USD estimate by 2.22 K%. Revenue for the same period reached 406.56 M USD, despite the estimate of 151.32 M USD. For the next quarter, analysts expect 0.05 USD in earnings per share and 151.66 M USD in revenue.
Next report date—
Report period—
EPS estimate—
Revenue estimate—
EPS
Reported
Estimate
Reported
Estimate
Surprise
Revenue
Reported
Estimate
Reported
Estimate
Surprise